Rasburicase
- Atc Codes:V03AF07
- CAS Codes:134774-45-1
- PHARMGKB ID:134774-45-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Fasturtec; Belgium: Fasturtec; Bulgaria: Fasturtec; Cyprus: Fasturtec; Czech Republic: Fasturtec; Denmark: Fasturtec; Estonia: Fasturtec; Finland: Fasturtec; France: Fasturtec; Germany: Fasturtec; Greece: Fasturtec; Hungary: Fasturtec; Ireland: Fasturtec; Italy: Fasturtec; Latvia: Fasturtec; Lithuania: Fasturtec; Luxembourg: Fasturtec; Malta: Fasturtec; Netherlands: Fasturtec; Poland: Fasturtec; Portugal: Fasturtec; Romania: Fasturtec; Slovakia: Fasturtec; Slovenia: Fasturtec; Spain: Fasturtec; Sweden: Fasturtec; UK: Fasturtec.
North America
Canada: Fasturtec; USA: Elitek.
Latin America
Brazil: Fasturtec.
Drug combinations
Chemistry
Rasburicase: C~1523~H~2383~N~417~O~462~S~7~ (monomer). Mw: approx. 34151.65 (1) Oxidase, urate (Aspergillus flavus clone 9C/9A reduced); (2) Urate oxydase (tetramer of the N-acetylpolypeptide of 301 aa). CAS-134774-45-1 (2000).
Pharmacologic Category
Enzymes; Urate-Oxidase Enzyme (Recombinant). (ATC-Code: V03AF07).
Mechanism of action
Converts uric acid to allantoin (inactive, soluble metabolite of uric acid). Does not inhibit formation of uric acid.
Therapeutic use
Initial management of uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies receiving anticancer therapy expected to result in tumor lysis and elevation of plasma uric acid.
Pregnancy and lactiation implications
Reproduction studies not conducted. Excretion in breast milk unknown (not recommended in nursing women).
Unlabeled use
Prevention and treatment of malignancy-associated hyperuricemia in adults.
Contraindications
Hypersensitivity, hemolytic or methemoglobinemia reactions to rasburicase or any component of the formulation. G6PD deficiency.
Warnings and precautions
Anaphylaxis/hypersensitivity reactions may occur at any time during treatment. Hemolysis may be associated with G6PD deficiency. Use contraindicated in G6PD deficiency. Discontinue immediately and permanently in any patient developing methemoglobinemia. Rasburicase is immunogenic and can elicit antibody response.